Citations

Clear

5626 citation(s) found for "Anderson, KS".

A first-in-human multi-center phase 1/2 study of a selective FGFR2/3 inhibitor, CGT4859, in patients with intrahepatic cholangiocarcinomas or other advanced solid tumors.
Ellis, Haley , Ahnert, Jordi Rodon, Starodub, Alexander, Ali, Akza, Moynihan, Kevin, Little, Meredith, Zou, Liangxing, Lawrence, Julia, Vogel, Arndt, Vogel, Arndt , Vogel, Arndt , Goyal, Lipika , Borad, Mitesh J. , Kim, Richard D. , Ahnert, Jordi Rodon, Valle, Juan W. , Bridgewater, John , Russell, Jeffery Scott , Ali, Akza

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps3171 Get It

TPS3171 Background: Genetic alterations in fibroblast growth factor receptors 2 and 3 ( FGFR2/3 ) occur in nearly all cancer types. FGFR2 fusions and rearrangements occur in up to 10-15% of intrahepatic cholangiocarcinomas (iCCA) and alterations in FGFR3 occur in 15-30% of urothelial cancers. The clinical benefit from currently approved FGFR inhibitors (FGFRi) is often curtailed by development of acquired resistance, which may arise through on-target mutations in the FGFR2/3 kinase domain. Additionally, off-tumor effects on FGFR1 by pan-FGFRi can lead to hyperphosphatemia and consequently to dose reductions or dose holds. Thus, there is an unmet clinical need for a selective FGFR2/3 inhibitor that has clinical efficacy against activating alterations and resistance mutations without causing FGFR1-mediated hyperphosphatemia. CGT4859 is an orally bioavailable, ATP-competitive, reversible inhibitor of FGFR2/3, with potency against clinically relevant FGFR2/3 kinase domain mutations. In addition, CGT4859 demonstrates >140 fold selectivity over FGFR1, and shows robust efficacy in target altered in vivo tumor models without increases in serum phosphorus. Nonclinical pharmacokinetics (PK) and safety data support evaluating CGT4859 in a first-in-human, open-label, dose-escalation and signal-seeking Phase I/II study (NCT06777316). Safety, tolerability, PK, pharmacodynamics, and antitumor activity of CGT4859 will be assessed in adults with histologically confirmed unresectable or metastatic iCCA or other solid tumors with FGFR2/3 alterations. Methods: CGT4859 will be administered orally continuously in 28-day cycles to patients (N=~50) at a starting dose of 1 mg QD, and dose escalation will not exceed 40 mg QD as determined using a Bayesian optimal interval design with backfill (BF-BOIN). This approach will be used to guide dose escalation and establish the maximum tolerated dose (MTD) and recommended Phase 2 Dose (RP2D). BF-BOIN enables backfilling of participants to doses that are cleared for safety during the dose escalation, generating additional data on safety and tolerability below the MTD. Objective response rate (ORR) and disease control rate will be determined based on investigator assessment using RECIST v1.1. Phase II will enroll up to 4 cohorts, each enrolling ~15 patients. Proposed cohorts will include participants who have iCCA and are either FGFRi-naïve or FGFRi-exposed. Two additional cohorts with other advanced solid tumors harboring FGFR2/3 alterations may be included based on signals detected in dose escalation. The primary efficacy endpoint for Phase II is ORR per RECIST v1.1. The preclinical data support the study of CGT4859 in this patient population with solid tumors harboring FGFR2 and/or FGFR3 genetic alterations. The phase I dose escalation study is currently enrolling at sites in the United States. Clinical trial information: NCT06777316 .
Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial.
Ulrickson, Matthew L. , Wong, Deborah J. , Sunwoo, John B. , Molina, Julian R. , Maloney, David G. , Bayne, Harry E. Fuentes, Grierson, Patrick , Langeberg, Wendy J., Go, William Y., Ng, Eric Wai-Choi , Welch, John S. , Hecht, J. Randolph, Specht, Jennifer M. , Specht, Jennifer , Kirtane, Kedar , Park, Jong Chul , Maus, Marcela V , Punekar, Salman R. , Locke, Frederick L. , Davila, Marco L , Shatsky, Rebecca

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps2677 Get It

TPS2677 Background: Despite the success in hematologic malignancies, CAR T therapies face significant challenges in solid tumors due to the lack of tumor-specific targets that distinguish cancer from normal cells. EGFR plays a critical role in oncogenesis across several cancers and is often upregulated (TCGA 2022). While monoclonal antibodies targeting EGFR have demonstrated efficacy, these approaches are often limited by on-target, off-tumor toxicities, such as skin rash, which constrains dose escalation and efficacy (Macdonald, et al. J Am Acad Dermatol . 2015). A2B395 is an allogeneic, logic-gated, EGFR-targeted Tmod CAR T therapy designed to address these limitations and provide a convenient and consistent off-the-shelf option. This therapy incorporates 2 CARs: an activator targeting EGFR, and a blocker targeting HLA-A*02. The activator recognizes EGFR on both tumor and normal cells, while the blocker inhibits CAR T activity against normal cells with preserved HLA expression and decreases the risk for graft-versus-host disease (Hamburger, et al. Mol Immunol . 2020). To address potential host-vs-graft response, an shRNA expression module targeting B2M is included in the Tmod construct, which significantly reduces major histocompatibility complex class I levels and subsequent host immune response (DiAndreth, et al. Clin Immunol. 2022). Importantly, the Tmod system is modular and adaptable to multiple targets. Initial data on autologous Tmod CAR T therapy suggest reduced off-tumor toxicity and encouraging clinical efficacy (Grierson, et al. SITC 2024. Abstract 588). A2B395 represents a novel approach for EGFR-expressing solid tumors with HLA-A*02 LOH. Methods: DENALI-1 (NCT06682793) is a phase 1/2, open-label, nonrandomized study evaluating the safety and efficacy of A2B395 in adults. Patients are enrolled through BASECAMP-1 (NCT04981119), a master prescreening study that identifies patients with HLA LOH at any time in the course of their disease via next-generation sequencing (Tempus AI, Inc.). Key inclusion criteria include histologically confirmed recurrent unresectable, locally advanced, or metastatic cancers associated with EGFR expression, including colorectal, non-small cell lung, squamous cell head and neck, triple negative breast, and renal cell cancers. Patients must have received ≥1 line of prior therapy, such as a checkpoint inhibitor, molecular targeted therapy, or chemotherapy. The primary objective of phase 1 is to evaluate safety, tolerability, and the recommended phase 2 dose (RP2D) using a Bayesian optimal interval design for dose escalation. The dose-expansion phase will confirm RP2D and collect biomarker data. Phase 2 will assess overall response rate per RECIST v1.1. Clinical trial information: NCT06682793 .
BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): Clinical update and first report of pharmacokinetics (PK) and
Arbour, Kathryn C. , George, Ben , Henry, Jason T. , Leventakos, Konstantinos , Ahnert, Jordi Rodon, Papadopoulos, Kyriakos P. , Perez, Cesar A. , Zuniga, Richard, Wozniak, A., Chin, Curtis D., Mazzei, Antonella , Hu, Zheyi , Simpson, Tyler R., Dickinson, Adam , Jänne, Pasi A. , Ahnert, Jordi Rodon, Johnson, Melissa L. , Spira, Alexander I. , Babiker, Hani M. , Haddox, Candace L. , Chin, Curtis

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3011-3011

10.1200/jco.2025.43.16_suppl.3011 Get It

3011 Background: BMS-986504 selectively binds to the PRMT5-MTA complex, which represents a synthetic lethal target in MTAP -del cancer cells, while sparing MTAP– wild-type cells. In the first-in-human phase 1/2 CA240-0007 study in advanced, unresectable or metastatic solid tumors with homozygous MTAP -del, BMS-986504 was found to be well tolerated and demonstrated antitumor activity in multiple tumors. Here, we report clinical results and the first PK and PD analyses of BMS-986504 from the dose escalation and expansion phases of CA240-0007. Methods: Pts with measurable/evaluable disease and no available treatment (Tx) with curative intent were enrolled; 7 doses were evaluated (50 to 800 mg) in dose escalation. Objective response rate (ORR), disease control rate (DCR), duration of response (DOR), time to response (TTR), safety, PK, PD, including plasma SDMA were assessed. Results: As of 2 Dec 24, 152 heavily pretreated pts were enrolled across all doses: NSCLC (n = 34), PDAC (n = 41), cholangiocarcinoma (n = 12), and mesothelioma (n = 12) were the most common tumor types. With a median f/u of 9.0 mo (95% CI 7.6–9.9), continued durable antitumor activity and deepening tumor regression were seen across tumor types and doses (ORR = 23%, DCR = 70%, median DOR = 10.5 mo, TTR = 4.6 mo). No new safety signals were identified. Most Tx-related adverse events (TRAEs) were grade (Gr) 1 or 2; 13% had Gr ≥ 3 TRAEs (Gr 3 = 12%, Gr 4 = < 1%, Gr 5 = 0). Doses from 50 to 600 mg QD were assessed for PK/PD. The AUC (0-24) after multiple doses was approximately dose proportional at 200 to 600 mg, and the terminal t 1/2 after a single dose was approximately 24 h (table). There were dose-dependent reductions in predicted plasma SDMA, with the 400 and 600 mg doses approaching the plateau. Conclusions: With longer f/u, BMS-986504 continued to show increasingly durable antitumor activity. BMS-986504 demonstrated a favorable PK/PD profile, supporting QD dosing at 400 and 600 mg. These results support further investigation of BMS-986504 at 400 and 600 mg QD as a potential first-in-class synthetic lethal Tx option in pts with advanced solid tumors with MTAP -del. Clinical trial information: NCT05245500 . PK and PD. 50 mg QD 100 mg QD 200 mg QD 400 mg QD 600 mg QD PK after multiple doses t max a (min–max), h 2.0 (2.0–4.0)n = 3 2.0 (1.0–2.0)n = 3 2.0 (0.5–6.0)n = 8 2.0 (0.5–4.0)n = 10 2.0 (1.0–6.0)n = 10 C max , b ng/mL 107n = 3 377n = 3 685n = 8 1240n = 10 2110n = 10 AUC (0-24) , b h∙ng/mL 948 n = 3 3060 n = 3 7150 n = 7 11,800n = 10 26,700n = 9 AUC (0-24) , b,c h∙ng/mL/mg 19.0n = 3 30.6n = 3 35.8n = 7 29.5n = 10 44.6n = 9 Terminal t 1/2 after single dose, d h 21.7 n = 1 80.7 n = 1 21.5 n = 14 21.7 n = 14 24.1 n = 1 PD Translational exposure targets (C avgss ), X 0.08 0.21 0.5 1.1 1.7 Predicted plasma SDMA reduction, a % (90% PI) 30.0 (23.2–37.8) 38.8 (27.1–47.5) 48.3 (42.0–53.0) 55.0 (50.7–57.6) 57.4 (54.3–59.0) a Median. b Geometric mean. c Dose-normalized. d Arithmetic mean.
Longitudinal analysis of pain-induced brain activations in post-traumatic headache
Ku, Dohyun , Mao, Lingchao, Nikolova, Simona , Dumkrieger, Gina , Ross, Katherine , Huentelman, Matthew J. , Anderson, Trent , Porreca, Frank , Navratilova, Edita , Starling, Amaal J. , Li, Jing , Mao, Lingchao , Dumkrieger, Gina , Starling, Amaal, Chong, Catherine D , Schwedt, Todd J , Mao, Lingchao , Porreca, Frank , Navratilova, Edita , Wu, Teresa , Chong, Catherine D. , Schwedt, Todd J.

Mayo Clinic

Cephalalgia | May 28, 2025 | Volume: 45 | Issue: 5 | Pages: No page available

10.1177/03331024251345160 | PMID 40426297 Get It

Background Headache is a common symptom following mild traumatic brain injury (mTBI). Post-traumatic headache (PTH), a secondary headache disorder that develops after mTBI, often persists for months or years. To identify potential recovery mechanisms and prognostic biomarkers, the present study investigated whether longitudinal changes in pain-induced brain activation differ between healthy controls (HC) and PTH participants showing headache improvement and those without improvement. Methods Thirty-three participants who met International Classification of Headache Disorders, 3rd edition, criteria for acute PTH within 59 days post-mTBI and 33 HC participants were included with no significant differences in demographics. All participants underwent functional magnetic resonance imaging scans at baseline, four weeks, and 16 weeks post-enrollment using a thermal stimulation paradigm with noxious and non-painful heat stimuli. ‘Painful vs. Non-Painful Heat’ contrasts were generated using SPM12. PTH improvement was assessed at three months post-enrollment via electronic headache diaries. Two-sample t -tests compared the brain activation between HC and PTH at baseline. Linear mixed-effects models examined longitudinal changes for HC, PTH improvement and non-improvement groups across visits. Generalized linear models compared these groups within visits. Results Baseline analysis revealed several regions with significantly higher activation in acute PTH compared to HC, including bilateral postcentral gyrus, right superior temporal gyrus, right middle temporal gyrus, left inferior parietal gyrus, right superior parietal gyrus, left ventral striatum, left olfactory cortex, left gyrus rectus, and left middle occipital gyrus. Over time, the PTH improvement group demonstrated progressive normalization across all identified brain regions, whereas the non-improvement group showed only partial normalization in left ventral striatum, left olfactory cortex, and left gyrus rectus. Sustained elevated activation in specific regions distinguished PTH participants without headache improvement from those with headache improvement, suggesting potential biomarkers for persistent PTH. Conclusions Our findings demonstrate significantly altered pain-induced brain activations in participants with acute PTH compared to HC. Longitudinal analysis revealed distinct recovery trajectories: progressive normalization in the improvement group versus persistent alterations in the non-improvement group. These neuroimaging patterns may serve as biomarkers for identifying individuals at risk for persistent PTH, with implications for early intervention and personalized treatment approaches.
Variability in Health Care Utilization and Perioperative Outcomes Among Urinary Diversion Patients: Analysis of the National Surgical Quality Improvement Program Database
Fadel, Anthony , Pinkhasov, Alexander M., Sharma, Vidit , Anderson, Katherine T. , Viers, Boyd R. , Fadel, Anthony , Findlay, Bridget L. , Pinkhasov, Alexander M.

Mayo Clinic

Urology Practice | May 27, 2025 | Volume: 12 | Issue: 5 | Pages: 548-556

10.1097/upj.0000000000000839 | PMID 40423528 Get It

Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool
Hawkes, Will, Woodward, Gary , Hamza, Izhan, Desai, Viral , Barrett‐O’Keefe, Zachary , Grogan, Martha, Davison, Halley, Maurer, Mathew S. , Helmke, Stephen , Scherrer‐Crosbie, Marielle , Soltani, Marwa , Goyal, Akash , Zaręba, Karolina M. , Cheng, Richard K. , Vieira, Marcelo Luiz Campos , Elissamburu, Pablo , Ronderos, Ricardo , Prado, Aldo , Sarswat, Nitasha , Addetia, Karima , Ruberg, Frederick L. , Randazzo, Michael , Al-Roub, Nora , Kidd, Liam, Lang, Roberto M. , Pellikka, Patricia A. , Barrett-O'Keefe, Zachary, Scott, Christopher , Davison, Halley N, Cheng, Richard , Kirkpatrick, James N , Koutroumpakis, Efstratios , Deswal, Anita M , Pursnani, Amit , Pellikka, Patricia A , Slivnick, Jeremy A. , Hawkes, Will, OLIVEIRA, JORGE COELHO , Akerman, Ashley, Gómez, Alberto , Grogan, Martha , Dispenzieri, Angela , Scott, Christopher G. , Cotella, Juan Ignacio , Maurer, Mathew S , Kitano, Tetsuji , Takeuchi, Masaaki , Hotta, Viviane Tiemi , Patel, Amit R. , Asch, Federico M. , O’Driscoll, Jamie M. , Strom, Jordan B. , Kidd, Liam, Cuddy, Sarah A. M. , Upton, Ross

Mayo Clinic

European Heart Journal | May 26, 2025 | Volume: 46 | Issue: 40 | Pages: 4090-4101

10.1093/eurheartj/ehaf387 | PMID 40631729 Get It

Abstract Background and Aims Accurate differentiation of cardiac amyloidosis (CA) from phenotypic mimics remains challenging using current clinical and echocardiographic techniques. The accuracy of a novel artificial intelligence (AI) screening algorithm for echocardiography-based CA detection was assessed. Methods Utilizing a multisite, multiethnic dataset (n = 2612, 52% CA), a convolutional neural network was trained to differentiate CA from phenotypic controls using transthoracic apical four-chamber video clips. External validation was conducted globally across 18 sites including 597 CA cases and 2122 controls. Classification accuracy was assessed on the entire external validation dataset, and subgroup analyses were performed both on technetium pyrophosphate scintigraphy referrals, and individuals matched for age, sex, and wall thickness. Model accuracy was also compared with the transthyretin CA score and the increased wall thickness score within a subset of older heart failure with preserved ejection fraction patients with increased wall thickness. Results Cardiac amyloidosis patients and controls displayed similar age, sex, race, and comorbidities. After the removal of uncertain AI predictions (13%), model discrimination and classification were excellent for the entire external validation dataset [area under the receiver operating characteristic curve (AUROC) 0.93, sensitivity 85%, specificity 93%], irrespective of CA subtype (sensitivity: light-chain = 84%, wild-type transthyretin = 85%, and hereditary transthyretin = 86%). Performance was maintained in subgroup analysis in patients clinically referred for technetium pyrophosphate scintigraphy imaging (AUROC 0.86, sensitivity 77%, specificity 86%) and matched patients (AUROC 0.92, sensitivity 84%, specificity 91%). The AI model (AUROC 0.93) also outperformed transthyretin CA score (AUROC 0.73) and increased wall thickness (AUROC 0.80) scores. Conclusions This AI screening model—using only an apical four-chamber view—effectively differentiated CA from other causes of increased left ventricular wall thickness.
Preoperative Radiotherapy in Patients With Localized Ewing Sarcoma Enrolled on AEWS1031: A Report From the Children's Oncology Group
Indelicato, Daniel J. , Callan, Alexandra K. , Krailo, Mark , DelRocco, Natalie , Buxton, Allen, Binitie, Odion , Christ, Alexander B. , Kessell, Sandy, Chuba, Paul J. , Nadel, Helen , Pawel, Bruce , DuBois, Steven G. , Janeway, Katherine A. , Leavey, Patrick J. , Mascarenhas, Leo , Ahmed, Safia K. , Binitie, Odion , Christ, Alexander B , DuBois, Steven G , Janeway, Katherine A , Leavey, Patrick , Mascarenhas, Leo , Laack, Nadia N Issa , Indelicato, Daniel J , Nadel, Helen , Görlick, Richard , Reed, Damon R. , Laack, Nadia N.

Mayo Clinic

Pediatric Blood & Cancer | May 26, 2025 | Volume: 72 | Issue: 8 | Pages: No page available

10.1002/pbc.31820 | PMID 40415235 Get It

AbstractPatients with resectable Ewing sarcoma (ES) in select sites, such as the pelvis or chest wall, have a higher risk of positive microscopic margins following surgery. AEWS1031 was the first North American/Australasia ES cooperative group trial allowing standardized preoperative radiotherapy, intended to minimize the morbidity of combined modality local tumor control as well as improve the likelihood of clear surgical margins. In this study, we found that the use of low‐dose preoperative radiation to a smaller target volume resulted in a high rate of R0 resection. The robust pathologic response rate strengthens existing evidence illustrating the radiosensitivity of Ewing sarcoma.
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage
Collaborators, GBD 2021 Global Subarachnoid Hemorrhage Risk Factors, Rautalin, Ilari, Stark, Benjamin, Johnson, Catherine O., Kaprio, Jaakko , Korja, Miikka, Krishnamurthi, Rita , Nair, Balakrishnan , Vergouwen, Mervyn D. I. , Abdelkader, Atef , Abdullahi, Auwal , Abualruz, Hasan , Abukhadijah, Hana J , Adamu, Lawan Hassan, Adegboye, Oyelola A. , Adzigbli, Leticia Akua, Agyemang‐Duah, Williams , Ahinkorah, Bright Opoku, Ahmad, Aqeel , Ahmad, Danish , Ahmadzade, Amir Mahmoud , Akkaif, Mohammed Ahmed , Ali, Mohammed Usman, Alif, Sheikh Mohammad , Alimohamadi, Yousef, Alsabri, Mohammed , Altaf, Awais , Alvis‐Guzmán, Nelson , Alwafi, Hassan , Al‐Wardat, Mohammad , Alyahya, Mohammad S. , Amin, Tarek Tawfik , Amindarolzarbi, Alireza , Amusa, Ganiyu , Angappan, Dhanalakshmi , Anuoluwa, Boluwatife Stephen, Anwar, Saleha, Anyasodor, Anayochukwu Edward , Apostol, Geminn Louis Carace, Areda, Demelash, Artamonov, Anton A, Artanti, Kurnia Dwi , Ashemo, Mubarek Yesse , Athar, Mohammad , Aujayeb, Avinash , Awotidebe, Adedapo Wasiu , Azadnajafabad, Sina , Aziz, Shahkaar , Bagheri, Nasser , Taqanaki, Pegah Bahrami , Bahramian, Saeed , Bai, Ruhai , Baig, Atif Amin , Baltatu, Ovidiu Constantin , Bam, Kiran, Barker‐Collo, Suzanne , Bärnighausen, Till , Bastan, Mohammad‐Mahdi , Basu, Sanjay , Bell, Shelly L, Benseñor, Isabela M , Berhie, Alemshet Yirga , Bhagavathula, Akshaya Srikanth , Bhaskar, Sonu , Bhat, Ajay Nagesh, Bhat, Vivek , Birhan, Mekuriaw Mesfin , Borhany, Hamed, Breitner, Susanne , Bulamu, Norma B. , Butt, Zahid A , Cabral, Lucas Scotta , Santos, Florentino Luciano Caetano dos , Cámera, Luis Alberto , Capodici, Angelo , Chadwick, Joshua , Chakraborty, Promit Ananyo , Chanie, Gashaw Sisay , Chattu, Vijay Kumar , Chi, Gerald, Chichagi, Fatemeh , Columbus, Alyssa , Criqui, Michael H, Ohadi, Mohammad Amin Dabbagh , Dadras, Omid , Dalli, Lachlan L. , Debopadhaya, Shayom , Dervišević, Emina , Devanbu, Vinoth Gnana Chellaiyan, Dewan, Syed Masudur Rahman , Dhane, Amol S. , Chi, Thanh, Phuong, Thao Huynh, Dohare, Sushil , Докова, Клара , Dowou, Robert Kokou , Dsouza, Haneil Larson , Dutta, Siddhartha , Dziedzic, Arkadiusz , E’mar, Abdel Rahman, Edvardsson, David , Efendi, Ferry, Nahas, Nevine El , Elgendy, Islam Y. , Eltaha, Chadi, Emeto, Theophilus I. , Fakhradiyev, Ildar , Faris, Pawan , Fauk, Nelsensius Klau , Fazylov, Timur, Fekadu, Ginenus , Fetensa, Getahun, Fischer, Florian, Foschi, Matteo , Fridayani, Ni Kadek Yuni, Gaipov, Abduzhappar , Gajjar, Avi A. , Ganesan, Balasankar , Gebregergis, Miglas Welay, Gebremeskel, Teferi Gebru , Getie, Molla , Ghadirian, Fataneh , Ghasemzadeh, Afsaneh , Gholamalizadeh, Maryam , Gil, Artyom , Goleij, Pouya , Goulart, Alessandra C. , Goulart, Bárbara Niegia Garcia de , Guan, Shi‐Yang , Gupta, Sapna , Habibzadeh, Farrokh , Hadi, Najah R, Hankey, Graeme J. , Harlianto, Netanja I. , Hasani, Hamidreza, Hasnain, Md Saquib , Haubold, Johannes , Havmoeller, Rasmus, Hay, Simon I , Hbid, Youssef , Heidari, Golnaz , Hiraike, Yuta, Hoan, Nguyen Quoc , Hosseinzadeh, Mehdi , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ikiroma, Adalia , Isola, Gaetano , Iwagami, Masao , Jacob, Louis, Jain, Akhil, Jakovljević, Mihajlo , Jatau, Abubakar Ibrahim , Jawaid, Talha, Jayapal, Sathish Kumar , Jonas, Jost B, Joseph, Nitin , Jürisson, Mikk , Kadashetti, Vidya, Kalani, Rizwan, Kamireddy, Arun , Kandel, Himal , Behnagh, Arman Karimi , Kashoo, Faizan , Kayode, Gbenga A , Kazemi, Foad , Khader, Yousef , Khaing, Inn Kynn , Khan, Fayaz Ahmad , Khan, Mohammad Jobair , Kashani, Hamid Reza Khayat , Khosla, Atulya Aman , Kim, Kwanghyun , Kim, Yun Jin , Korzh, Oleksii , Krishan, Kewal , Krishna, Varun, Krishnamoorthy, Vijay , Kuddus, Mohammed , Kulimbet, Mukhtar , Lahariya, Chandrakant, Lai, Daphne Teck Ching , Lai, Hanpeng , Laksono, Tri, Lallukka, Tea , Latifinaibin, Kaveh, Le, Nhi Huu Hanh, Le, Thao T. , Lee, Munjae , Lee, Yo Han , Lenzi, Jacopo , Leonardi, Matilde, Li, Ming‐Chieh , Li, Xiaopan , Lim, Stephen S , Lin, Jialing , Saute, Ricardo Lutzky , Malik, Ahmad Azam , Marateb, Hamid Reza , Maroufi, Seyed Farzad , Maugeri, Andrea , McPhail, Steven , Mehndiratta, Man Mohan, Mestrovic, Tomislav, Mettananda, Chamila Dinushi Kukulege , Miazgowski, Tomasz , Minervini, Giuseppe , Mithra, Prasanna , Mohamed, Abdalla Z. , Mohammad, Ameen Mosa , Mohammed, Shafiu , Moni, Mohammad Ali , Moradi, Yousef, Moraga, Paula , Morawska, Lídia , Munjal, Kavita , Murray, Christopher J L , Nagarajan, Ahamarshan Jayaraman , Naik, Ganesh R. , Najdaghi, Soroush , Davani, Delaram Narimani , DELETE-ME, Nawsherwan, Nazri-Panjaki, Athare , Negoi, Ruxandra Irina , Nematollahi, Soroush , Nguyen, Hau Thi Hien, Nguyen, Hau Thi Hien, Nguyen, Phat Tuan , Nguyễn, Văn Thành , Niazi, Robina Khan, Nikoobar, Ali , Sá, Antonio Tolentino Nogueira de , Nomura, Shuhei , Nzoputam, Chimezie Igwegbe , Oancea, Bogdan , Ojo-Akosile, Tolulope R, Oliveira, Gláucia Maria Moraes de , Olorukooba, Abdulhakeem Abayomi , Osuagwu, Uchechukwu Levi , Ouyahia, Amel, A, Mahesh Padukudru P, Panagiotakos, Demosthenes B. , Parikh, Romil R., Park, Seoyeon , Pedersini, Paolo , Peprah, Emmanuel , Perico, Norberto, Petermann-Rocha, Fanny Emily, Plotnikov, Evgenii , Полибин, Р. В. , Postma, Maarten J. , Prasad, Manya , Qian, Gangzhen , Rahmanian, Mohammad , Rajaa, Sathish , Rajput, Prashant , Ramadan, Mahmoud M. , Rane, Amey, Rashidi, Mohammad‐Mahdi , Razo, Christian , Reddy, Murali Mohan Rama Krishna, Remuzzi, Giuseppe, Rezaei, Negar , Rezaeian, Mohsen , Rocha, Hermano Alexandre Lima , Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo , Romoli, Michele, Romozzi, Marina, Roy, Nitai , Saddik, Basema Ahmad, Sahoo, Pragyan Monalisa , Salaroli, Luciane Bresciani , Samuel, Vijaya Paul, Samy, Abdallah M , Santric-Milicevic, Milena M., Saravanan, Aswini, Schlaich, Markus P. , Sethi, Yashendra , Seylani, Allen, Shaaban, Ahmed Nabil , Shafie, Mahan , Shaikh, Summaiya Zareen , Shamsutdinova, Alfiya, Sharifan, Amin , Rad, Javad Sharifi, Sharma, Vishal, Shashamo, Bereket Beyene , Shetty, Premalatha K, Shigematsu, Mika, Shorofi, Seyed Afshin, Singh, Paramdeep , Singh, Puneetpal , Singh, Surjit , Sobia, Farrukh , Solanki, Shipra, Soraneh, Soroush , Spartalis, Michael, Srinivasamurthy, Suresh Kumar , Stanikzai, Muhammad Haroon , Sun, Zhong , Swain, Chandan Kumar , Damavandi, Payam Tabaee , Tabatabaeizadeh, Seyed-Amir, Tabche, Celine , Taiba, Jabeen , Tamuzi, Jacques Lukenze , Tan, Ker‐Kan , Teramoto, Masayuki , Thakur, Ramna, Thankappan, Kavumpurathu Raman , Thayakaran, Rasiah , Thirunavukkarasu, Sathish, Ticoalu, Jansje Henny Vera, Tiwari, Krishna Raj , Tonelli, Marcello , Topór-Mądry, Roman , Tovani-Palone, Marcos Roberto Roberto, Tran, Jasmine, Tran, Thang Huu , Duc, Nguyen Tran Minh , Truelsen, Thomas Clement, Unim, Brigid, Vahdati, Sanaz, Vaithinathan, Asokan Govindaraj , Eynde, Jef Van den , Vladimirov, Sergey Konstantinovitch , Waheed, Yasir, Wahood, Waseem , Walde, Mandaras Tariku, Wang, Yanzhong , Wickramasinghe, Nuwan Darshana , Wolfe, Charles D. A., Wubie, Yihun Miskir, Xiao, Hong , Xu, Xiaoyue , Yano, Yuichiro , Yarahmadi, Amir , Ye, Pengpeng, Yon, Dong Keon , Zanghì, Aurora , Zare, Iman, Zastrozhin, Michael, Zhang, Zhi-Jiang , Zhang, Zhiqiang , Zhang, Zhiqiang, Zhao, Hanqing , Zhou, Shang Cheng, Zhumagaliuly, Abzal , Zia, Hafsa, Roth, Gregory A., Topór‐Mądry, Roman , Oliveira, Arão Belitardo , Rahim, Fakher , Saddik, Basema , Waheed, Yasir , Liu, Xuefeng , Zhang, Yunquan , Ozair, Ahmad , Buendía, Jefferson Antonio , Korja, Miikka , Baig, Atif Amin , Shanawaz, Mohd , Elgendy, Islam Y , Hankey, Graeme J , Alif, Sheikh M , Rezaei, Negar , Bhagavathula, Akshaya Srikanth , Van den Eynde, Jef , Ozair, Ahmad , Collaborators, GBD 2021 Global Subarachnoid Hemorrhage Risk Factors, Rautalin, Ilari Matias , Volovici, Victor , Ranta, Annemarei , Rinkel, Gabriël J.E. , Abate, Yohannes Habtegiorgis, Abbastabar, Hedayat , Abd-Allah, Foad , Abdi, Parsa , Abdollahi, Arash , Abiodun, Olugbenga Olusola , Aboagye, Richard Gyan , Abouzid, Mohamed , Abtahi, Dariush , Abu‐Rumeileh, Samir , Abualhasan, Ahmed , Abu‐Zaid, Ahmed , Addo, Isaac Yeboah , Adedoyin, Rufus Adesoji , Adra, Saryia , Ahinkorah, Bright Opoku , Ahmed, Ali , Ahmed, Haroon , Ahmed, Syed Anees , Aji, Budi , Al‐Ajlouni, Yazan A. , Al‐Aly, Ziyad , ALBashtawy, Mohammed , Aljunid, Syed Mohamed , Alomari, Mahmoud A. , Alrawashdeh, Ahmad , Alsabri, Mohammed A., Salman, Rustam Al‐Shahi , Al‐Tammemi, Ala’a B. , Al‐Worafi, Yaser Mohammed , Aly, Hany Z. , Alzoubi, Karem Hasan , Amani, Reza, Anderlini, Deanna , Anil, Abhishek , Arabloo, Jalal , Ärnlöv, Johan , Arumugam, Ashokan , Aryan, Zahra , Jafarabadi, Mohammad Asghari , Ashraf, Tahira , Athari, Seyyed Shamsadin , Azzam, Ahmed Y , Babu, Giridhara R. , Bako, Abdulaziz Tijjani , Banach, Maciej , Bandyopadhyay, Soham , Banik, Biswajit , Bardhan, Mainak , Barqawi, Hiba Jawdat , Barua, Lingkan , Beyene, Kebede Abera , Bhat, Vivek, Bhatti, Gurjit Kaur , Bhatti, Jasvinder Singh , Bijani, Ali , Bikbov, Boris , Birhanu, Mulugeta Molla , Bitra, Veera Raghavulu , Boloor, Archith , Brenner, Hermann , Bugiardini, Raffaele , Călina, Daniela Cornelia , Campos, Luciana Aparecida , Campos‐Nonato, Ismael , Carvalho, Félix , Castañeda-Orjuela, Carlos A , Catapano, Alberico Luigi , Cegolon, Luca , Chakraborty, Chiranjib , Chakraborty, Sandip , Chandika, Rama Mohan , Chaudhary, Anis Ahmad , Chi, Gerald , Ching, Patrick R , Chopra, Hitesh , Choudhari, Sonali Gajanan , Chowdhury, E. , Chu, Dinh‐Toi , Chung, Sheng‐Chia , Silva, Alanna Gomes da , Dai, Xiaochen , Dalal, Koustuv , D’Amico, Emanuele , Dashti, Mohsen , Davletov, Kairat , Cruz-Góngora, Vanessa Vianey De la , Delgado‐Enciso, Iván , Devanbu, Vinoth Gnana Chellaiyan, Dibas, Mahmoud , Doheim, Mohamed Fahmy , Dongarwar, Deepa , D’Oria, Mario , Doshi, Ojas Prakashbhai , Doshi, Rajkumar , Efendi, Defi , Efendi, Ferry , Elhadi, Muhammed , Eltahir, Mohd. Elmagzoub , Fabin, Natalia , Fagbamigbe, Adeniyi Francis , Fahim, Ayesha , Fares, Jawad , Ferreira, Nuno Bravo , Gandhi, Aravind P. , Garg, Ravindra Kumar , Gebrehiwot, Mesfin , Ghadimi, Delaram J. , Ghahramani, Sulmaz , Ghazy, Ramy Mohamed , Ghozy, Sherief , Gilani, Jaleed Ahmed , Gnedovskaya, Elena V. , Hadei, Mostafa , Hamidi, Samer , Hanifi, Nasrin , Haro, Josep María , Hasan, Faizul , Tabatabaei, Mahgol Sadat Hassan Zadeh , Heidari, Mohammad , Hemmati, Mehdi , Holla, Ramesh , Hostiuc, Sorin , Huang, Junjie , Huynh, Hong-Han , Ikeda, Nayu , Ilaghi, Mehran , Ilesanmi, Olayinka Stephen , Ilić, Irena , Ilić, Milena , Islam, Md. Rabiul , Ismail, Nahlah Elkudssiah , Iso, Hiroyasu , Jafarzadeh, Abdollah , Jairoun, Ammar Abdulrahman , Kalani, Rizwan, Kamal, Vineet Kumar , Kanchan, Tanuj , Karami, Jafar , Karaye, Ibraheem M. , Karimi, Yeganeh , Kesse‐Guyot, Emmanuelle , Khan, Fayaz, Khatatbeh, Haitham , Khatatbeh, Moawiah Mohammad , Kheirallah, Khalid Ahmed , Khidri, Feriha Fatima , Khormali, Moein , Kısa, Adnan , Kısa, Sezer , Kivimäki, Mika , Kolahi, Ali‐Asghar , Kompani, Farzad , Kostev, Karel , Kothari, Nikhil , Kunutsor, Setor K. , Kurniasari, Maria Dyah , Kusuma, Dian Palupi , Kytö, Ville , Vecchia, Carlo La , Lahariya, Chandrakant , Latief, Kamaluddin , Lee, Seung Won , Lee, Wei‐Chen , Leonardi, Matilde, Liu, Xuefeng , Lohner, Valerie , Lorenzovici, László , Lotufo, Paulo A. , Lucchetti, Giancarlo , Lusk, Jay B. , Amin, Hawraz Ibrahim M. , Malhotra, Armaan Kush , Malhotra, Kashish , Malta, Déborah Carvalho , Mansournia, Mohammad Alì , Mantovani, LG , Manu, Emmanuel, Marino, Mirko , Martínez, Ramón , Martini, Santi , Martorell, Miquel , Marzo, Roy Rillera , Mathangasinghe, Yasith , Mathews, Elezebeth , Mehmood, Asim , Mehrabani-Zeinabad, Kamran , Menezes, Ritesh G. , Meo, Sultan A , Meretoja, Atte , Meštrović, Tomislav , Sá, Ana Carolina Micheletti Gomide Nogueira de , Minh, Le Huu Nhat , Mirică, Andreea , Мirrakhimov, Erkin М , Mirza‐Aghazadeh‐Attari, Mohammad , Mishra, Ajay Kumar , Mohamed, Ahmed Ismail , Mohammadi, Soheil , Mohammadian-Hafshejani, Abdollah , Mokdad, Ali H. , Molinaro, Sabrina , Momani, Shaher , Ghalibaf, AmirAli Moodi , Moradi, Maryam , Msherghi, Ahmed A.A. , Ansari, Noureddin Nakhostin , Nargus, Shumaila , Natto, Zuhair S. , Nauman, Javaid , DELETE-ME, Nawsherwan, Nayak, Vinod C , Newton, Charles R. , Nigatu, Yeshambel T. , Noubiap, Jean Jacques , Nugen, Fred , Oduro, Michael Safo , Okati‐Aliabad, Hassan , Okeke, Sylvester Reuben , Okekunle, Akinkunmi Paul , Olagunju, Andrew T , Olaiya, Muideen Tunbosun , Olufadewa, Isaac Iyinoluwa , Ornello, Raffaele , Ortiz‐Prado, Esteban , Ouyahia, Amel , Owolabi, Mayowa , Padrón‐Monedero, Alicia , Padubidri, Jagadish Rao , Panos, Leonidas D , Pantazopoulos, Ioannis N. , Parikh, Romil R., Patel, Jay , Patel, Urvish , Patoulias, Dimitrios , Pereira, Gavin F , Perianayagam, Arokiasamy , Perna, Simone , Petermann‐Rocha, Fanny , Philip, Anil K. , Пирадов, М. А. , Pradhan, Jalandhar , Puvvula, Jagadeesh , Qasim, Nameer Hashim , Raggi, Alberto , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Rahmani, Amir Masoud , Sanati, Ali Rajabpour , Ramasamy, Shakthi Kumaran , Ramazanu, Sheena , Rathish, Devarajan , Rawaf, Salman , Redwan, Elrashdy M , Remuzzi, Giuseppe , Romoli, Michele, Romozzi, Marina , Ross, Allen Guy , Rout, Himanshu Sekhar , Roy, Priyanka , Saad, Aly M A , Saadatian, Zahra , Sabour, Siamak , Sacco, Simona , Sadeghi, Erfan , Saeed, Usman, Sharif‐Askari, Fatemeh Saheb , Sahebkar, Amirhossein , Sajib, Md Refat Uz Zaman , Saleh, Mohamed A. , Samodra, Yoseph Leonardo , MİLİCEVİC, Milena Santric, Saravanan, Aswini , Sarkar, Tanmay, Sarode, Sachin Chakradhar , Sartorius, Benn , Satpathy, Maheswar , Schneider, Ione Jayce Ceola , Schuermans, Art , Selvaraj, Siddharthan , Senthilkumaran, Subramanian , Sepanlou, Sadaf Ghajarieh , Shahwan, Moyad Jamal , Shamim, Muhammad Aaqib , Shamsi, Anas , Shannawaz, Mohammed , Rad, Javad Sharifi, Sharma, Vishal , Shittu, Aminu , Shiue, Ivy , Shlobin, Nathan A. , Siddig, Emmanuel Edwar , Spartalis, Michael , Stanaway, Jeffrey D , Starodubova, Antonina Vladimirovna , Szarpak, Łukasz , Tabatabaeizadeh, Seyed‐Amir , Tabatabaeizadeh, Seyed-Amir, Talaat, Iman Mamdouh , Temsah, Mohamad‐Hani , Thakur, Ramna , Thirunavukkarasu, Sathish, Tiwari, Krishna, Truyen, Thien Tan Tri Tai , Tsai, Daniel Hsiang‐Te , Ullah, Atta , Unnikrishnan, Bhaskaran , Unsworth, Carolyn Anne, Usman, Jibrin Sammani , Valizadeh, Rohollah , Varghese, Joe , Vasankari, Tommi Juhani , Venketasubramanian, Narayanaswamy , Vervoort, Dominique , Villafañe, Jorge Hugo , Vinayak, Manish , Wafa, Hatem A , Walde, Mandaras Tariku, Willeit, Peter , Wolfe, Charles D.A. , Wolfe, Charles D. A., Yamagishi, Kazumasa , Yaribeygi, Habib , Yaya, Sanni , Ye, Pengpeng, Yonemoto, Naohiro , Yu, Chuanhua , Zastrozhin, Michael, Zhang, Chen , Zhang, Zhiqiang, Zielińska, Magdalena , Zyoud, Samer H. , Roth, Gregory A. , Feigin, Valery L. , Kulimbet, Mukhtar , Rahim, Fakher

Mayo Clinic

JAMA Neurology | May 23, 2025 | Volume: 82 | Issue: 8 | Pages: 765

10.1001/jamaneurol.2025.1522 | PMID 40406922 Get It

Importance Nontraumatic subarachnoid hemorrhage (SAH) represents the third most common stroke type with unique etiologies, risk factors, diagnostics, and treatments. Nevertheless, epidemiological studies often cluster SAH with other stroke types leaving its distinct burden estimates obscure. Objective To estimate the worldwide burden of SAH. Design, Setting, and Participants Based on the repeated cross-sectional Global Burden of Disease (GBD) 2021 study, the global burden of SAH in 1990 to 2021 was estimated. Moreover, the SAH burden was compared with other diseases, and its associations with 14 individual risk factors were investigated with available data in the GBD 2021 study. The GBD study included the burden estimates of nontraumatic SAH among all ages in 204 countries and territories between 1990 and 2021. Exposures SAH and 14 modifiable risk factors. Main Outcomes and Measures Absolute numbers and age-standardized rates with 95% uncertainty intervals (UIs) of SAH incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) as well as risk factor–specific population attributable fractions (PAFs). Results In 2021, the global age-standardized SAH incidence was 8.3 (95% UI, 7.3-9.5), prevalence was 92.2 (95% UI, 84.1-100.6), mortality was 4.2 (95% UI, 3.7-4.8), and DALY rate was 125.2 (95% UI, 110.5-142.6) per 100 000 people. The highest burden estimates were found in Latin America, the Caribbean, Oceania, and high-income Asia Pacific. Although the absolute number of SAH cases increased, especially in regions with a low sociodemographic index, all age-standardized burden rates decreased between 1990 and 2021: the incidence by 28.8% (95% UI, 25.7%-31.6%), prevalence by 16.1% (95% UI, 14.8%-17.7%), mortality by 56.1% (95% UI, 40.7%-64.3%), and DALY rate by 54.6% (95% UI, 42.8%-61.9%). Of 300 diseases, SAH ranked as the 36th most common cause of death and 59th most common cause of DALY in the world. Of all worldwide SAH-related DALYs, 71.6% (95% UI, 63.8%-78.6%) were associated with the 14 modeled risk factors of which high systolic blood pressure (population attributable fraction [PAF] = 51.6%; 95% UI, 38.0%-62.6%) and smoking (PAF = 14.4%; 95% UI, 12.4%-16.5%) had the highest attribution. Conclusions and Relevance Although the global age-standardized burden rates of SAH more than halved over the last 3 decades, SAH remained one of the most common cardiovascular and neurological causes of death and disabilities in the world, with increasing absolute case numbers. These findings suggest evidence for the potential health benefits of proactive public health planning and resource allocation toward the prevention of SAH.
Global multi‐specialty clinician perspectives on the implementation of Alzheimer's disease blood biomarkers
Rodda, Joanne , Kuchenbecker, Lindsey A. , Chabrashvili, Tinatin, Budelier, Melissa M. , Duran‐Aniotz, Claudia , Udeh‐Momoh, Chinedu , Akman‐Anderson, Leyla, Pereira, Ana C. , Keshavan, Ashvini , Keshavan, Ashvini , Borelli, Wyllians Vendramini , DeMarco, Mari L. , Castilhos, Raphael Machado , Cawston, Erin E. , Mielke, Michelle M. , Algeciras‐Schimnich, Alicia

Mayo Clinic

Alzheimer's & Dementia | May 22, 2025 | Volume: 21 | Issue: 5 | Pages: No page available

10.1002/alz.70201 | PMID 40401661 Get It

Abstract INTRODUCTION Clinicians’ views on the clinical readiness of Alzheimer's disease (AD) blood biomarkers (BBMs) are not well understood. METHODS The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Biofluid‐Based Biomarkers Professional Interest Area conducted a survey to elicit clinician opinions on AD BBM implementation, including contexts of use, assay selection, reporting, and result interpretation. RESULTS Clinician respondents ( n = 212) practiced in Europe (56%), North America (24%), the Caribbean and Central/South America (11%), and other continents (9%). Most respondents were medical doctors (80%) practicing in secondary or tertiary care (88%). For 56%, cerebrospinal fluid AD biomarkers or amyloid positron emission tomography were accessible, but 48% agreed and 52% disagreed with the implementation of AD BBMs in any clinical context. Respondents emphasized the need for data from diverse populations and educational resources to support test interpretation. DISCUSSION Surveyed clinicians generally agreed with published appropriate use recommendations but were divided on AD BBM readiness for clinical use. Highlights A survey of clinicians was conducted regarding clinical readiness of Alzheimer's disease (AD) blood biomarkers (BBMs). Views were split on AD BBM clinical readiness: 48% agreed, 52% disagreed. Most responders supported AD BBM use for treatment decisions. Most responders opposed AD BBM testing in asymptomatic individuals. Test performance data and educational materials to aid interpretation were of high importance.
A multicenter, propensity score-matched analysis of functional outcomes and recanalization success with or without Trevo for Medium and distal vessel occlusion
Siegler, James E. , Koneru, Manisha , Shaikh, Hamza, Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Yedavalli, Vivek , Tjoumakaris, Stavropoula , Henninger, Nils , Sundararajan, Sri Hari , Tan, Benjamin Yong‐Qiang , Heit, Jeremy J , Regenhardt, Robert W. , Kass‐Hout, Tareq , Fiehler, Jens, Puri, Ajit S , Dyzmann, Christian , Barreau, Xavier, Renieri, Leonardo, Filipe, João Pedro , Harker, Pablo, Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric, Abdalkader, Mohamad , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus A, Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Khalife, Jane, Rana, Ankit, Guenego, Adrien , Investigators, for the MAD MT, Heit, Jeremy J. , Salim, Hamza , Tjoumakaris, Stavropoula , Henninger, Nils , Kühn, Anna Luisa , Ghozy, Sherief , Scarcia, Luca , Regenhardt, Robert W , Morsi, Rami Z , Vigilante, Nicholas , Rouchaud, Aymeric , Essibayi, Muhammed Amir , Dyzmann, Christian , Colasurdo, Marco , Filipe, João Pedro , Alexandru Radu, Răzvan , Ota, Takahiro , Jabbour, Pascal , Klein, Piers , Nguyen, Thanh N , Altschul, David J , Gonzalez, Nestor R , Griessenauer, Christoph J , Liebeskind, David S. , Tancredi, Illario , Guenego, Adrien , Dmytriw, Adam A , Heit, Jeremy J , Musmar, Basel , Yedavalli, Vivek S , Siegler, James E , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Daraghma, Motaz , Kühn, Anna Luisa , Ghozy, Sherief , Morsi, Rami Z. , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Sheth, Sunil A , Essibayi, Muhammed Amir , Colasurdo, Marco , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Mowla, Ashkan , Jabbour, Pascal , Clarençon, Frédéric , Klein, Piers , Nguyen, Thanh N. , Möhlenbruch, Markus , Costalat, Vincent , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Mendes Pereira, Vitor , Khalife, Jane , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

Interventional Neuroradiology | May 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251341603 | PMID 40398470 Get It

Background Endovascular therapy (EVT) for stroke due to distal or medium vessel occlusion (DMVO) is safe. Due to the distinct anatomical characteristics of DMVOs, further evaluation of EVT is crucial to determine which devices may yield better outcomes. Methods A retrospective analysis of adults with DMVO treated in 37 centers (11 countries) was queried. The primary outcome of favorable shift in 90-day modified Rankin Scale (mRS) was compared between patients treated with Trevo versus other devices on first pass using 1:1 propensity score matching (PSM) with multivariable adjustment. Secondary outcomes included the number of pass attempts, final thrombolysis in cerebral infarction (TICI) score 2b-3, symptomatic intracranial hemorrhage (sICH), improvement in National Institutes of Health Stroke Scale (NIHSS) at 24h, and 90-day mortality. Results Of the 1115 included patients, 264 (24%) were treated with Trevo (PSM cohort of 261 per group). Trevo use was not associated with a favorable 90-day mRS shift (proportional odds ratio [OR] 1.10, 95% confidence interval [CI] 0.80–1.51). Trevo was associated with fewer passes (adjusted β=-0.25, 95% CI −0.48 - −0.03), higher odds of TICI 2b-3 (adjusted OR 1.97, 95% CI 1.11–3.49), and a greater 24h NIHSS improvement (adjusted β= −1.74, 95% CI −3.11 - −0.36), with no difference in sICH or mortality (p>0.05). Results were similar in sensitivity analyses. Conclusions We observed no safety concerns with Trevo as compared to other EVT devices for DMVO recanalization. There was a signal of better technical efficacy and early clinical improvement.